Portale Epatite e malattie del fegato
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. Indicazioni terapeutiche approvate da EMA

    2. Hézode C. et al., Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial, Lancet. 2015 Mar;

    3. Sulkowski MS. Et al.,  Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.JAMA. 2015 Mar;

    4. Chayama K. et al.,  Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015 May;

    5. Poordad F. et al.,  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May

    6. Ferenci P.,  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May

    7. Zeuzem S. et al,  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Ap

    8. Feld JJ et al., Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr

    9. Kwo PY et al.,  An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med. 2014 Dec

    10. a - TURQUOISE-III Study: ombitasvir/paritaprevir/ritonavir + dasabuvir for genotype 1b with cirrhosis - Feld JJ. J Hepatol 2016; 64:301-7

    11. X – Co-Formulated Ombitasvir and Paritaprevir/ritonavir with ribavirinm in adults with Hepatitis C Virus Genotype 4 infection and Cirrhosis /AGATE-I): a randomised open-label trial

    12. Asselah et al. – Lancet Gastroenterology 2016


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!